DK2185933T3 - Matriptaseprotein og anvendelser deraf - Google Patents

Matriptaseprotein og anvendelser deraf Download PDF

Info

Publication number
DK2185933T3
DK2185933T3 DK08795130.7T DK08795130T DK2185933T3 DK 2185933 T3 DK2185933 T3 DK 2185933T3 DK 08795130 T DK08795130 T DK 08795130T DK 2185933 T3 DK2185933 T3 DK 2185933T3
Authority
DK
Denmark
Prior art keywords
cancer
antibody
matriptase
antibodies
stem
Prior art date
Application number
DK08795130.7T
Other languages
English (en)
Inventor
Christian Rohlff
Jonathan Alexander Terrett
Original Assignee
Oxford Biotherapeutics Ltd
Squibb & Sons Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Biotherapeutics Ltd, Squibb & Sons Llc filed Critical Oxford Biotherapeutics Ltd
Application granted granted Critical
Publication of DK2185933T3 publication Critical patent/DK2185933T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (11)

1. Affinitetsreagens, der er i stand til specifikt at binde sig til matriptasestammen, der befinder sig på celleoverfladen, hvor matriptasestammen har sekvensen defineret i en hvilken som helst af SEQ ID NO: 10-13 eller en sekvens med mindst 80 % identitet med en hvilken som helst af SEQ ID NO: 10-13, og hvor affinitetsreagenset er konjugeret til en terapeutisk del, eventuelt hvor den terapeutiske del er en cytotoksisk del eller en radioaktiv del.
2. Affinitetsreagens ifølge krav 1, hvor matriptasestammen er defineret af en hvilken som helst af SEQ ID NO: 10-13 eller et polypeptid med 90 % eller 95 % identitet med en hvilken som helst af SEQ ID NO: 10-13.
3. Affinitetsreagens, der specifikt binder til et polypeptid med sekvensen ifølge en hvilken som helst af SEQ ID NO: 10-13, eller et polypeptid med 90 % eller 95 % identitet med en hvilken som helst af SEQ ID NO: 10-13, hvor polypeptidet befinder sig på en overflade af en celle, og hvor affinitetsreagenset ikke specifikt bindes til SEQ ID NO: 1, og hvor affinitetsreagenset er konjugeret til en terapeutisk del, eventuelt hvor den terapeutiske del er en cytotoksisk del eller en radioaktiv del.
4. Affinitetsreagens ifølge et hvilket som helst af kravene 1 til 3, hvilket reagens er et antistof, antistoffragment deraf eller antistofderivat deraf.
5. Affinitetsreagens ifølge krav 4, hvor affinitetsreagenset er et isoleret monoklonalt antistof, eller en antigen-bindende del deraf, eller et antistofmimetikum, og hvor det isolerede monoklonale antistof eventuelt er udvalgt fra gruppen bestående af et fuldlængde-antistof af en IgGl-, IgG2-, IgG3- eller IgG4-isotype, et humaniseret antistof, et enkeltkæde-antistof, et immunkonjugat, et defucosyleret antistof og et bispecifikt antistof.
6. Affinitetsreagens ifølge krav 4, hvor affinitetsreagenset er et antistoffragment udvalgt fra gruppen bestående af et UniBody, et domæneantistof og et Nanobody.
7. Affinitetsreagens ifølge krav 5, hvor affinitetsreagenset er et antistofmimetikum udvalgt fra gruppen bestående af et Affibody, et DARPin, et Anticalin, et Avimer, et Versabody og et Duocalin.
8. Affinitetsreagens ifølge krav 4, hvilket affinitetsreagens er et monoklonalt antistof, der har cytotoksicitet over for celler, der udtrykker matriptasestammeantigen i nærvær af et humant komplement eller i nærvær af humane immune effektorceller.
9. Farmaceutisk sammensætning omfattende en terapeutisk effektiv mængde af et eller flere affinitetsreagenser som defineret i et hvilket som helst af kravene 1 til 8 og et farmaceutisk acceptabelt fortyndingsmiddel eller bærestof.
10. Affinitetsreagens som defineret i et hvilket som helst af kravene 1 til 8 eller sammensætning som defineret i krav 9 til anvendelse ved behandling eller forebyggelse af sygdom, såsom cancer, hvilken cancer eventuelt er udvalgt fra gruppen bestående af brystcancer, colorektalcancer, esophaguscancer, gastrisk cancer, prostatacancer eller uteruscancer.
11. Kit, der indeholder et eller flere affinitetsreagenser ifølge et hvilket som helst af kravene 1 til 8 eller indeholder en sammensætning som defineret i krav 9, hvor affinitetsreagenset er egnet til anvendelse i behandling og/eller diagnose.
DK08795130.7T 2007-08-07 2008-08-07 Matriptaseprotein og anvendelser deraf DK2185933T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96383707P 2007-08-07 2007-08-07
PCT/US2008/009512 WO2009020645A2 (en) 2007-08-07 2008-08-07 Matriptase protein and uses thereof

Publications (1)

Publication Number Publication Date
DK2185933T3 true DK2185933T3 (da) 2015-10-26

Family

ID=40239716

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08795130.7T DK2185933T3 (da) 2007-08-07 2008-08-07 Matriptaseprotein og anvendelser deraf

Country Status (7)

Country Link
US (1) US8420091B2 (da)
EP (1) EP2185933B1 (da)
JP (2) JP5864856B2 (da)
AU (1) AU2008284271B2 (da)
DK (1) DK2185933T3 (da)
ES (1) ES2550754T3 (da)
WO (1) WO2009020645A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
US20120294800A1 (en) * 2009-01-07 2012-11-22 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
CN102341412B (zh) * 2009-03-05 2018-01-05 梅达雷克斯有限责任公司 特异于cadm1 的全人抗体
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
EP2904015A4 (en) 2012-10-02 2016-10-05 Univ Rutgers TARGETED RELEASE OF ANTIBODIES TO ACTIVATED MATRIPTASE-CONJUGATED TOXINS
KR20160079818A (ko) * 2013-11-25 2016-07-06 옥스포드 바이오테라퓨틱스 리미티드 암 치료용 항-매트립타제 항체
KR102441107B1 (ko) * 2014-11-07 2022-09-13 후지쿠라 가세이 가부시키가이샤 데옥시하이푸신·신타제 유전자를 지표로서 사용하는 동맥 경화 및 암의 검출 방법
CA3017958C (en) 2016-03-18 2024-03-12 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
US7022821B1 (en) 1998-02-20 2006-04-04 O'brien Timothy J Antibody kit for the detection of TADG-15 protein
EP1161266A4 (en) 1999-03-12 2007-09-19 Univ Georgetown Matriptase, a serine protease and its applications
US7030231B1 (en) 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
CA2388450C (en) * 1999-10-20 2013-02-12 The Board Of Trustees Of The University Of Arkansas Tadg-15: an extracellular serine protease overexpressed in carcinomas
US6447978B1 (en) 1999-12-03 2002-09-10 Kodak Polychrome Graphics Llc Imaging member containing heat switchable polymer and method of use
EP1252300B1 (en) 2000-02-03 2011-01-19 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
US6903201B2 (en) 2001-01-05 2005-06-07 Curagen Corporation Proteins and nucleic acids encoding same
WO2002072786A2 (en) 2001-03-13 2002-09-19 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
AU2002254357A1 (en) 2001-03-22 2002-10-08 Dendreon Corporation Nucleic acid molecules encoding serine protease cvsp14, the encoded polypeptides and methods based thereon
CA2442089A1 (en) 2001-03-27 2002-10-03 Dendreon San Diego Llc Nucleic acid molecules encoding a transmembran serine protease 9, the encoded polypeptides and methods based thereon
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7019019B2 (en) 2002-12-23 2006-03-28 Dendreon Corporation Matriptase inhibitors and methods of use
CN1985489B (zh) 2004-07-09 2012-05-09 艾利森电话股份有限公司 在多媒体通信系统中提供不同服务的方法和装置
CA2592249C (en) 2004-12-20 2014-07-29 Amgen Fremont Inc. Binding proteins specific for human matriptase
WO2006090389A2 (en) 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
EP1938104A2 (en) * 2005-10-17 2008-07-02 Institute for Systems Biology Tissue-and serum-derived glycoproteins and methods of their use

Also Published As

Publication number Publication date
JP5864856B2 (ja) 2016-02-17
EP2185933A2 (en) 2010-05-19
EP2185933B1 (en) 2015-10-07
ES2550754T3 (es) 2015-11-12
WO2009020645A2 (en) 2009-02-12
JP2010535506A (ja) 2010-11-25
JP2014223083A (ja) 2014-12-04
AU2008284271B2 (en) 2014-03-13
US20100285017A1 (en) 2010-11-11
US8420091B2 (en) 2013-04-16
AU2008284271A1 (en) 2009-02-12
WO2009020645A3 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
JP5945381B2 (ja) タンパク質
DK2185933T3 (da) Matriptaseprotein og anvendelser deraf
US20190310255A1 (en) Proteins
US8084034B2 (en) Proteins
EP2200636B1 (en) Protein
US20110229480A1 (en) Pta072 protein
DK2447719T3 (da) Proteiner
EP2297580B1 (en) Antibody against Ephrin Type-A receptor 7 for treatment of bladder cancer
US20120058131A1 (en) Pta089 protein